Blood mRNA biomarkers distinguish variable systemic and sputum inflammation at treatment initiation of inhaled antibiotics in cystic fibrosis: A prospective non-randomized trial.

Blood mRNA biomarkers distinguish variable systemic and sputum inflammation at treatment initiation of inhaled antibiotics in cystic fibrosis: A prospective non-randomized trial.

Inhaled antibiotics control chronic airway infection and maintain respiratory health in cystic fibrosis (CF). Given variation in patient responses to inhaled antibiotics, the ability to identify distinct responder phenotypes would facilitate the delivery of personalized care. Previously, a 10-gene p...

Full description

Bibliographic Details
Main Authors: Silvia M Caceres, Linda A Sanders, Noel M Rysavy, Katie R Poch, Caroline R Jones, Kyle Pickard, Tasha E Fingerlin, Roland A Marcus, Kenneth C Malcolm, Jennifer L Taylor-Cousar, David P Nichols, Jerry A Nick, Matthew Strand, Milene T Saavedra
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2022-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0267592

Internet

https://doi.org/10.1371/journal.pone.0267592

Similar Items